Aethlon Medical, Inc.
AEMD · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.05 | -0.07 |
| FCF Yield | -68,826.00% | -37.42% | -14.36% | -29.15% |
| EV / EBITDA | 1,984.39 | -0.05 | -5.73 | -0.55 |
| Quality | ||||
| ROIC | -0.04% | -34.71% | -33.82% | -40.76% |
| Gross Margin | 0.00% | 50.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.12 | 0.97 | 0.27 | 1.15 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -102,562.74% | 17.02% | 9.10% | -26.72% |
| Safety | ||||
| Net Debt / EBITDA | 1,985.94 | -0.65 | 2.37 | 2.15 |
| Interest Coverage | 0.00 | -198.24 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -332.04 | -573.63 | -656.04 | -0.06 |